Market Place
Sourcing Support
Lexeo Therapeutics: Q4 & FY 2025 Results & Operational Highlights
30 Mar 2026 //
GLOBENEWSWIRE
Lexeo Therapeutics Joins February Investor Conferences
05 Feb 2026 //
GLOBENEWSWIRE
Lexeo Enhances Cardiovascular Team, Expands Cardiac Therapeutics
27 Jan 2026 //
GLOBENEWSWIRE
Lexeo Therapeutics Reports Encouraging Phase I/II Results
12 Jan 2026 //
GLOBENEWSWIRE
Lexeo, J&J Team Up On Heart Pump Tech For Gene Therapy Delivery
08 Jan 2026 //
GLOBENEWSWIRE
Lexeo Therapeutics Hosts Virtual KOL Event at CVCT Forum
04 Dec 2025 //
GLOBENEWSWIRE
Lexeo Therapeutics Unveils Q3 2025 Financials & Operations Update
05 Nov 2025 //
GLOBENEWSWIRE
Lexeo Closes Public Offering, Private Placement & Full Option
20 Oct 2025 //
GLOBENEWSWIRE
Lexeo Therapeutics Plans Stock Offering And Pre-Funded Warrants
16 Oct 2025 //
GLOBENEWSWIRE
Lexeo Therapeutics Reports Q2 2025 Financial Results
14 Aug 2025 //
GLOBENEWSWIRE
Lexeo PXV venBio Partner on Cardiac RNA Therapeutics
24 Jun 2025 //
GLOBENEWSWIRE
Lexeo Therapeutics Announces $80M Equity Financing
27 May 2025 //
GLOBENEWSWIRE
Lexeo laid off 15% in April to focus on cardiac gene therapies
12 May 2025 //
FIERCE BIOTECH
Lexeo Therapeutics Reports Q1 2025 Financial Results
12 May 2025 //
GLOBENEWSWIRE
Lexeo Therapeutics to Present New CMC Data at ASGCT Meeting
01 May 2025 //
GLOBENEWSWIRE
Lexeo Therapeutics Reports 2024 Financial Results and Highlights
24 Mar 2025 //
GLOBENEWSWIRE
Lexeo Therapeutics to Present at 43rd J.P. Morgan Conference
07 Jan 2025 //
GLOBENEWSWIRE
Lexeo Therapeutics Appoints Kyle as Chief Financial Officer
19 Dec 2024 //
GLOBENEWSWIRE
Lexeo Therapeutics Updates on Cardiac Portfolio & Q3 Results
13 Nov 2024 //
GLOBENEWSWIRE
Lexeo Encouraging Early Data for Alzheimer’s Gene Therapy
31 Oct 2024 //
GLOBENEWSWIRE
Lexeo Therapeutics Presents LX1001 Alzheimer’s Data at CTAD
30 Oct 2024 //
GLOBENEWSWIRE
Lexeo To Present Interim Data From LX1001 At CTAD 2024
22 Oct 2024 //
GLOBENEWSWIRE
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
05 Sep 2024 //
GLOBENEWSWIRE
Lexeo Therapeutics Reports Q2 2024 Results And Operational Highlights
12 Aug 2024 //
GLOBENEWSWIRE
Lexeo In-Licenses LX2006 For FA Cardiomyopathy
22 Apr 2024 //
GLOBENEWSWIRE
Lexeo wins fast track designation for Friedreich’s ataxia gene therapy
17 Apr 2024 //
PHARMACEUTICAL TECHNOLOGY
Lexeo`s LX2006 Granted FDA Fast Track for Friedreich`s Ataxia Cardiomyopathy
16 Apr 2024 //
GLOBENEWSWIRE
Lexeo pencils in $113M IPO for Alzheimer`s gene therapy readouts in 2024
30 Oct 2023 //
ENDPTS
Two biotechs go public while Apnimed bides its time
02 Oct 2023 //
FIERCE BIOTECH
Lexeo and Abivax seek Nasdaq listings in shrinking window for biotech IPOs
29 Sep 2023 //
ENDPTS
LEXEO Announces Strategic Investment from Sarepta Therapeutics to Suppor LEXEO
28 Aug 2023 //
GLOBENEWSWIRE
LEXEO Announces Dosing in Second Cohort in Phase 1/2 Trial of LX2006
13 Jun 2023 //
GLOBENEWSWIRE
LEXEO Therapeutics Announces Data Presentations at the (ASGCT) Annual Meeting
02 May 2023 //
GLOBENEWSWIRE
LEXEO Therapeutics Appoints Micah Zajic as Chief Financial Officer
05 Jan 2023 //
GLOBENEWSWIRE
LEXEO Therapeutics to Present at the 41st Annual J.P. Morgan Conference
03 Jan 2023 //
GLOBENEWSWIRE
